Meningitis, Meningococcal
A fulminant infection of the meninges and subarachnoid fluid by the bacterium NEISSERIA MENINGITIDIS, producing diffuse inflammation and peri-meningeal venous thromboses. Clinical manifestations include FEVER, nuchal rigidity, SEIZURES, severe HEADACHE, petechial rash, stupor, focal neurologic deficits, HYDROCEPHALUS, and COMA. The organism is usually transmitted via nasopharyngeal secretions and is a leading cause of meningitis in children and young adults. Organisms from Neisseria meningitidis serogroups A, B, C, Y, and W-135 have been reported to cause meningitis. (From Adams et al., Principles of Neurology, 6th ed, pp689-701; Curr Opin Pediatr 1998 Feb;10(1):13-8)
Subtype terms (1)
More specific conditions that are subtypes of Meningitis, Meningococcal in the MeSH hierarchy.
Drugs by status
Approved for this indication (12)
- meningococcal (groups A, C, Y, W) CRM197 conjugate vaccine
- serogroup b meningococcal vaccine
- meningococcal (groups A, C, Y, W) tetanus toxoid conjugate vaccine
- sulphisomidine
- monovalent group c meningococcal vaccine
- quadrivalent groups a, c, y, and w-135 meningococcal vaccine
- meningococcal (group B) vaccine
- HibMenCY
- meningococcal (groups A, C, Y, W) diphtheria toxoid conjugate vaccine
- Monovalent group A meningococcal vaccine
- Monovalent group C meningococcal vaccine
- Bivalent group A and C meningococcal vaccine
Phase 4 trials (6)
Phase 3 trials (18)
- DTaP, inactivated poliovirus, haemophilus influenzae b conjugate, hepatitis b vaccine
- menjugate
- hepatitis b vaccine (recombinant)
- typhoid vi polysaccharide vaccine
- hepatitis a vaccine, inactivated
- inactivated japanese encephalitis vaccine
- multi-valent pneumococcal conjugate vaccine
- acyw135 mcv
- live attenuated varicella vaccine
- pneumococcal 7-valent conjugate vaccine
- measles, mumps, rubella, varicella vaccine
- measles, mumps, and rubella vaccine
- haemophilus influenzae type b conjugate vaccine
- acellular pertussis vaccine (including diptheria and tetanus toxoids)
- hepatitis-a virus (inactivated) / hepatitis-b surface antigen
- nmcv-5
- meningococcal groups a, b, c, w, and Y vaccine
- Inactivated polio virus - Enhanced
Organizations
Organization Involved with Phase 4 Indications (12)
Organization Involved with Phase 3 Indications (9)
Organization Involved with Phase 2 Indications (10)
- Wyeth
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- JN-International Medical Corporation
- World Health Organization
- Addis Ababa University
- Armauer Hansen Research Institute, Ethiopia
- Health Protection Agency, United Kingdom
- Chesapeake Research Group, LLC
- IRC Clinics, Towson
- People's Liberation Army of China
Organization Involved with Phase 1 Indications (2)
Organization Involved with Other Experimental Indications (1)